Surgery improves outcomes for gastroenteropancreatic neuroendocrine tumors with liver metastasis.

• Patients undergoing primary resection and metastasectomy for small-bowel neuroendocrine tumors (sbnets) had a mean disease-specific survival of 97 months, compared to 71.6 months for pancreatic neuroendocrine tumors (pnets).
• Surgical candidates who refused surgery had notably worse outcomes, with mean survivals of 73.5 months for sbnets and 56.5 months for pnets.

Surgeons should prioritize surgical intervention for eligible patients, as it significantly enhances survival.

• Both resection strategies were performed more frequently on sbnets than pnets (41% vs. 26%).